[go: up one dir, main page]

WO2007033208A3 - Use of indirubin and its derivatives in the treatments of hiv infection and heart failure - Google Patents

Use of indirubin and its derivatives in the treatments of hiv infection and heart failure Download PDF

Info

Publication number
WO2007033208A3
WO2007033208A3 PCT/US2006/035559 US2006035559W WO2007033208A3 WO 2007033208 A3 WO2007033208 A3 WO 2007033208A3 US 2006035559 W US2006035559 W US 2006035559W WO 2007033208 A3 WO2007033208 A3 WO 2007033208A3
Authority
WO
WIPO (PCT)
Prior art keywords
indirubin
derivatives
polypeptide sequence
heart failure
treatments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/035559
Other languages
French (fr)
Other versions
WO2007033208A2 (en
Inventor
Robert Redfield
Alonso Heredia
Charles E Davis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Maryland Biotechnology Institute
Original Assignee
The University of Maryland Biotechnology Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University of Maryland Biotechnology Institute filed Critical The University of Maryland Biotechnology Institute
Publication of WO2007033208A2 publication Critical patent/WO2007033208A2/en
Anticipated expiration legal-status Critical
Publication of WO2007033208A3 publication Critical patent/WO2007033208A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Indirubin and its derivatives are described for reduction of replication of human immunodeficiency virus. Such therapeutic agent and its derivatives are also described in application to reducing the effects of heart failure, by administration of indirubin or a functionally active derivative thereof to modify cardiac muscle cell hypertrophy. Indirubin and its functional derivatives may also be employed in antiviral combination therapy compositions containing therapeutically effective chimeric polypeptides containing a virus coat polypeptide sequence and a viral receptor polypeptide sequence wherein the virus coat polypeptide sequence and the viral receptor polypeptide sequence are linked and exhibit ligand/receptor binding affinity.
PCT/US2006/035559 2005-09-12 2006-09-12 Use of indirubin and its derivatives in the treatments of hiv infection and heart failure Ceased WO2007033208A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71609705P 2005-09-12 2005-09-12
US60/716,097 2005-09-12

Publications (2)

Publication Number Publication Date
WO2007033208A2 WO2007033208A2 (en) 2007-03-22
WO2007033208A3 true WO2007033208A3 (en) 2009-05-22

Family

ID=37865533

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/035559 Ceased WO2007033208A2 (en) 2005-09-12 2006-09-12 Use of indirubin and its derivatives in the treatments of hiv infection and heart failure

Country Status (1)

Country Link
WO (1) WO2007033208A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009111218A2 (en) * 2008-02-29 2009-09-11 Schering Corporation Ccr5 antagonists as prophylactics for preventing hiv infection and methods of inhibiting transmission of same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596539B1 (en) * 1997-10-31 2003-07-22 Maxygen, Inc. Modification of virus tropism and host range by viral genome shuffling
US20040254094A1 (en) * 2000-10-11 2004-12-16 The Trustees Of University Of Pennsylvania And Board Of Regents Suppression of cyclin kinase activity for prevention and treatment of infections
US20050154046A1 (en) * 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
US20050171038A1 (en) * 2004-01-30 2005-08-04 Agouron Pharmaceuticals, Inc. Therapeutic combinations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596539B1 (en) * 1997-10-31 2003-07-22 Maxygen, Inc. Modification of virus tropism and host range by viral genome shuffling
US20040254094A1 (en) * 2000-10-11 2004-12-16 The Trustees Of University Of Pennsylvania And Board Of Regents Suppression of cyclin kinase activity for prevention and treatment of infections
US20050154046A1 (en) * 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
US20050171038A1 (en) * 2004-01-30 2005-08-04 Agouron Pharmaceuticals, Inc. Therapeutic combinations

Also Published As

Publication number Publication date
WO2007033208A2 (en) 2007-03-22

Similar Documents

Publication Publication Date Title
WO2007022371A3 (en) Chemokine receptor binding compounds
CA2446435A1 (en) 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
HRP20130406T1 (en) Medicaments with hm74a receptor activity
AU2003249993A1 (en) PHENYL-(4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES
WO2005121145A3 (en) Octahydro-pyrrolo[3,4-c] derivatives and their use as antiviral compounds
EP1834637A4 (en) Preventive/therapeutic composition for free radical disease
WO2008057420A3 (en) Extended triterpene derivatives
WO2009093264A3 (en) Pharmaceutical combinations comprising specified age breaker and further drugs, i.a. antihypertensive drugs, antidiabetic drugs etc.
JP2002528502A5 (en)
WO2007046868A3 (en) Thiazolidine derivatives and their uses as therapeutic agents
BR112023000229A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, AND, PEPTIDE
RU2004135563A (en) MEDICINE FOR TREATING AN INCREASED ACTIVITY OF THE BLADDER
WO2005059107A3 (en) Chemokine receptor binding compounds
JP2004537500A5 (en)
CA2143610A1 (en) Use of norastemizole for the treatment of allergic disorders
WO2007064968A3 (en) Stable pharmaceutical compositions of 5,10 methylenetetrahydrofolate
WO2006138259A3 (en) Chemokine receptor binding compounds
NZ703919A (en) Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins
JP2003514025A5 (en)
WO2007033208A3 (en) Use of indirubin and its derivatives in the treatments of hiv infection and heart failure
AU2003283500A1 (en) 1,4-diazabicyclo(3.2.2)nonanecarboxamide derivatives, preparation and therapeutic use thereof related to malfunction of nicotinic receptors
WO2006125194A3 (en) Piperazine derivatives and their uses as therapeutic agents
WO2009071283A3 (en) Therapeutic use of desacyl ghrelin
WO2011014009A3 (en) Novel di-substituted phenoxyacetyl-based compound or pharmaceutically acceptable salt thereof, production method for same and pharmaceutical composition for suppressing multiple drug resistance comprising same as an active ingredient
WO2022125378A8 (en) Combination therapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06803464

Country of ref document: EP

Kind code of ref document: A2